In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Understanding Cagrilintide: Benefits and Uses Development of Cagrilintide, a Long Acting Amylin Analogue Journal of Medicinal Chemistry Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3 eBioMedicine Cagri Peptide With Retatrutide: UK Evidence, Safety and Availability Bolt Pharmacy Understanding Semaglutide and Wegovy for Weight Loss Pronunciation Guide